PEGylated BODIPY Photosensitizer for Type I Dominant Photodynamic Therapy and Afterglow Imaging

• DOI: 10.1021/acsami.4c14754
• Publication Date: 2024-10-30T07:12:22Z
• Authors: Hui Wen; Qihang Wu; Xiujuan Xiang; Tingting Sun; Zhigang Xie; Xuesi Chen
• Keywords: BODIPY

Type I photodynamic therapy (PDT) exhibits outstanding therapeutic effects in hypoxic environments tumors, but the design of type photosensitizers (PSs), especially those with simple structures dramatic properties, remains a challenge. Herein, we report strategy for developing PSs one molecule afterglow luminescence. As proof concept, 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) PS (BIP) bearing water-soluble poly(ethylene glycol) (mPEG550) chains is synthesized, and BIP can self-assemble into nanoparticles (BIPNs). Interestingly, BIPNs exhibit an O2•--triggered luminescence, which scarce, BODIPY derivatives. demonstrate dominant PDT at ultralow dose under both normoxic environments, significantly inhibit tumor growth irradiation. This work highlights high-performance luminescence excellent effects, underscoring significant potential versatile clinical theranostics.